These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12560225)

  • 1. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
    Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G
    Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.
    Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
    Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL
    Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in mixed cryoglobulinemia: increased experience and perspectives.
    De Vita S; Quartuccio L; Fabris M
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S122-8. PubMed ID: 17936213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
    Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S
    Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
    Ahmed MS; Wong CF
    J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.
    Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F
    Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
    Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
    Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
    Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.
    Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M
    Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
    Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
    Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
    Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
    Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
    Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current therapeutic strategies for HCV-associated cryoglobulinemia].
    Iannuzzella F; Garini G
    Reumatismo; 2008; 60(3):163-73. PubMed ID: 18854876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literature.
    Terrier B; Marie I; Lacraz A; Belenotti P; Bonnet F; Chiche L; Graffin B; Hot A; Kahn JE; Michel C; Quemeneur T; de Saint-Martin L; Hermine O; Léger JM; Mariette X; Senet P; Plaisier E; Cacoub P
    J Autoimmun; 2015 Dec; 65():74-81. PubMed ID: 26320984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
    Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
    Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.